{
  "meta": {
    "title": "Stable_Ischemic_Heart_Disease_-_Management",
    "url": "https://brainandscalpel.vercel.app/stable-ischemic-heart-disease-management-e1e24b0a.html",
    "scrapedAt": "2025-11-29T18:24:41.508Z"
  },
  "questions": [
    {
      "id": 6659,
      "choices": [
        {
          "id": 26605,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol </span></span></span></p>"
        },
        {
          "id": 26606,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
        },
        {
          "id": 26607,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evolocumab </span></span></span></p>"
        },
        {
          "id": 26608,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pentoxifylline</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 76-year-old man with peripheral artery disease (PAD) and persistent claudication despite exercise and optimal medical therapy (aspirin, statin, enalapril). What is the most appropriate additional treatment?</span></span></p>",
      "unique_key": "Q1213381",
      "question_audio": null,
      "question_video": null,
      "map_id": 30630,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Cilostazol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol is a phosphodiesterase inhibitor that improves walking distance and reduces symptoms in patients with claudication due to PAD. It&#39;s recommended in addition to standard medical therapy for PAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Dual antiplatelet therapy is not routinely recommended for PAD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Evolocumab</span></strong><span style=\"font-size:12.0pt\">: PCSK9 inhibitors are for patients with high LDL cholesterol despite statin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pentoxifylline</span></strong><span style=\"font-size:12.0pt\">: Not proven effective for claudication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with peripheral artery disease and intermittent claudication, cilostazol is recommended to improve limb symptoms in addition to smoking cessation, aspirin, statin therapy, and supervised exercise.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol is contraindicated in patients with heart failure.</span></span></span></p>",
      "correct_choice_id": 26605,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6661,
      "choices": [
        {
          "id": 26613,
          "text": "<p><span style=\"font-size:12.0pt;\">Reteplase</span></p>"
        },
        {
          "id": 26614,
          "text": "<p><span style=\"font-size:12.0pt;\">Tirofiban</span></p>"
        },
        {
          "id": 26615,
          "text": "<p><span style=\"font-size:12.0pt;\">Enoxaparin</span></p>"
        },
        {
          "id": 26616,
          "text": "<p><span style=\"font-size:12.0pt;\">Emergent coronary angiography</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old woman with acute chest pain for the last 3 hours. Aspirin and clopidogrel was given in the ambulance. ECG is taken in ER and shown below. What is the next step?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-171044.png\" alt=\"\" width=\"400\" height=\"204\"></span></p>",
      "unique_key": "Q1878728",
      "question_audio": null,
      "question_video": null,
      "map_id": 30632,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>C) Enoxaparin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">ECG shows widespread ST segment depression, suggesting a diagnosis of acute coronary syndrome (ACS) without ST-elevation (NSTE-ACS). In patients with suspected NSTE-ACS, early administration of anticoagulation is crucial to prevent further thrombus formation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation</u>:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Reteplase</strong>: This is a thrombolytic agent used in STEMI and not in NSTE-ACS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Tirofiban</strong>: GpIIb/IIIa inhibitor used primarily during PCI under special circumstances.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Emergent Coronary angiography</strong>: While angiography is crucial to confirm the diagnosis and guide further management, immediate anticoagulation with enoxaparin should be initiated first. In this patient with ST depression (a high risk factor), URGENT coronary angiography is optimal (&lt; 24h) rather than immediate (&lt; 2h).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In patients with suspected NSTE-ACS, early administration of enoxaparin is crucial to prevent further thrombus formation while awaiting coronary angiography.</span></p>",
      "correct_choice_id": 26615,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6666,
      "choices": [
        {
          "id": 26633,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery bypass grafting (CABG) </span></span></span></p>"
        },
        {
          "id": 26634,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medical therapy without revascularization </span></span></span></p>"
        },
        {
          "id": 26635,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myocardial viability testing </span></span></span></p>"
        },
        {
          "id": 26636,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Percutaneous coronary intervention (PCI)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with exertional chest pain and a positive stress test undergoes angiography revealing complex multivessel coronary artery disease (CAD) involving the left main. He has a left ventricular ejection fraction (LVEF) of 42%. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q3897808",
      "question_audio": null,
      "question_video": null,
      "map_id": 30637,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Coronary artery bypass grafting (CABG)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CABG is the preferred revascularization strategy for patients with complex multivessel CAD, especially involving the left main, and with reduced LVEF. It offers superior survival benefits compared to medical therapy alone or PCI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Medical therapy</span></strong><span style=\"font-size:12.0pt\">: Insufficient for complex CAD and reduced LVEF, carries a higher risk of adverse events. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Viability testing</span></strong><span style=\"font-size:12.0pt\">: Not necessary before revascularization in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PCI</span></strong><span style=\"font-size:12.0pt\">: Less favorable than CABG for complex multivessel disease, especially with left main involvement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with multivessel coronary artery disease, coronary artery bypass grafting is associated with enhanced survival compared with medical therapy alone.</span></span></span></p>",
      "correct_choice_id": 26633,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6712,
      "choices": [
        {
          "id": 26817,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Furosemide </span></span></span></p>"
        },
        {
          "id": 26818,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitroglycerin </span></span></span></p>"
        },
        {
          "id": 26819,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil </span></span></span></p>"
        },
        {
          "id": 26820,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CPAP</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with a history of hypertension and coronary artery disease presents with acute decompensated heart failure. He is dyspneic at rest and has bibasilar crackles on lung auscultation. Which of the following medications is NOT appropriate for initial </span></span></p>",
      "unique_key": "Q7218827",
      "question_audio": null,
      "question_video": null,
      "map_id": 30645,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Verapamil</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil is a non-dihydropyridine calcium channel blocker. These medications are contraindicated in acute decompensated heart failure (ADHF) because they have negative inotropic effects, meaning they weaken the heart&#39;s ability to contract. This can worsen the patient&#39;s cardiac output and exacerbate heart failure symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Furosemide</span></strong><span style=\"font-size:12.0pt\">: Loop diuretic, cornerstone of therapy in ADHF to reduce fluid overload. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nitroglycerin</span></strong><span style=\"font-size:12.0pt\">: Vasodilator, used to reduce preload and afterload, improving cardiac function in ADHF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CPAP</span></strong><span style=\"font-size:12.0pt\">: Non-invasive ventilation, often used in ADHF to improve oxygenation and decrease the work of breathing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-dihydropyridine calcium channel blockers (like verapamil) are C/I in acute decompensated heart failure due to their negative inotropic effects</span></span></span></p>",
      "correct_choice_id": 26819,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6754,
      "choices": [
        {
          "id": 26985,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel</span></span></span></p>"
        },
        {
          "id": 26986,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose aspirin </span></span></span></p>"
        },
        {
          "id": 26987,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prasugrel </span></span></span></p>"
        },
        {
          "id": 26988,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with stable angina and aspirin allergy is undergoing lifestyle counseling and antianginal therapy. What is the most appropriate cardioprotective treatment?</span></span></p>",
      "unique_key": "Q7745718",
      "question_audio": null,
      "question_video": null,
      "map_id": 30651,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Clopidogrel</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel is recommended for secondary prevention in patients with stable ischemic heart disease who are intolerant or allergic to aspirin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Low-dose aspirin</span></strong><span style=\"font-size:12.0pt\">: Contraindicated due to aspirin allergy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Prasugrel</span></strong><span style=\"font-size:12.0pt\"> and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>D. Ticagrelor</strong>: More potent antiplatelet agents, typically used in acute coronary syndrome or after PCI, not as monotherapy for stable angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All patients with stable ischemic heart disease should receive guideline-directed therapies consisting of lifestyle modification, cardioprotective therapy, and antianginal medication.&nbsp;</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with stable ischemic heart disease should receive antiplatelet therapy (low-dose aspirin or clopidogrel in aspirin-intolerant patients) for secondary prevention of cardiovascular events.</span></span></span></p>",
      "correct_choice_id": 26985,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6577,
      "choices": [
        {
          "id": 26277,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous milrinone </span></span></span></p>"
        },
        {
          "id": 26278,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous nitroglycerin </span></span></span></p>"
        },
        {
          "id": 26279,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase furosemide </span></span></span></p>"
        },
        {
          "id": 26280,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start CVVH (Continuous venovenous hemofiltration)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with decompensated heart failure is hospitalized and treated with a maximal dose of IV furosemide. He has minimal urine output and persistent signs of volume overload. What is the most appropriate next step?</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>",
      "unique_key": "Q9337004",
      "question_audio": null,
      "question_video": null,
      "map_id": 30644,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Start CVVH (Continuous venovenous hemofiltration)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute decompensated heart failure (ADHF) who are unresponsive to maximal diuretic therapy (as evidenced by minimal urine output and persistent volume overload), the next step is to initiate ultrafiltration. CVVH is a form of renal replacement therapy that gently removes excess fluid over a longer period, making it well-suited for patients who may not tolerate the rapid fluid shifts of hemodialysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Add intravenous milrinone:</span></strong><span style=\"font-size:12.0pt\"> Milrinone is an inotrope used to improve cardiac contractility. While it may help with cardiac output, it doesn&#39;t directly address the volume overload and can worsen renal function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add intravenous nitroglycerin:</span></strong><span style=\"font-size:12.0pt\"> Nitroglycerin is a vasodilator that can reduce preload and afterload, but it&#39;s not the primary treatment for volume overload when diuretics fail.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase furosemide:</span></strong><span style=\"font-size:12.0pt\"> The patient is already on the maximal dose of furosemide, so further increases would not be effective and could lead to adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with ADHF who are unresponsive to maximal diuretic therapy, CVVH is a crucial intervention to manage volume overload and prevent further complications.</span></span></span></p>",
      "correct_choice_id": 26280,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6602,
      "choices": [
        {
          "id": 26377,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 month </span></span></span></p>"
        },
        {
          "id": 26378,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3 months </span></span></span></p>"
        },
        {
          "id": 26379,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 months </span></span></span></p>"
        },
        {
          "id": 26380,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">12 months</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with diabetes mellitus received a drug-eluting stent for non-ST elevation acute coronary syndrome (NSTE-ACS). She was started on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the recommended minimum duration of her antiplatelet therapy?</span></span></p>",
      "unique_key": "Q2994818",
      "question_audio": null,
      "question_video": null,
      "map_id": 30649,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) 12 months</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with diabetes who have received a drug-eluting stent for NSTE-ACS, the recommended minimum duration of DAPT (aspirin plus a P2Y12 inhibitor like clopidogrel) is <strong>12 months</strong>. This is due to the increased risk of stent thrombosis and major adverse cardiovascular events in patients with diabetes compared to those without.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 1 month:</span></strong><span style=\"font-size:12.0pt\"> This duration is too short and would significantly increase the risk of stent thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 3 months:</span></strong><span style=\"font-size:12.0pt\"> While some studies suggest shorter durations may be safe in select patients, the standard recommendation for patients with diabetes is 12 months.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. 6 months:</strong> This is the minimum duration for patients without diabetes who have received a drug-eluting stent for ACS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand the recommended duration of dual antiplatelet therapy in patients with diabetes who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents for acute coronary syndrome. </span></span></span></p>",
      "correct_choice_id": 26380,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6756,
      "choices": [
        {
          "id": 26993,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of clopidogrel </span></span></span></p>"
        },
        {
          "id": 26994,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of isosorbide mononitrate </span></span></span></p>"
        },
        {
          "id": 26995,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography </span></span></span></p>"
        },
        {
          "id": 26996,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise echocardiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 69-year-old man with persistent angina despite maximally tolerated antianginal therapy. He has orthostatic hypotension and current BP and PR are 100/60 mm Hg and 54/min respectively. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q1856672",
      "question_audio": null,
      "question_video": null,
      "map_id": 30652,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography is the most appropriate step to assess for obstructive coronary artery disease and guide potential revascularization to improve symptoms and quality of life.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Addition of Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Not indicated for stable angina without recent revascularization. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Addition of Isosorbide mononitrate</span></strong><span style=\"font-size:12.0pt\">: Adding more antianginal medication may not be helpful if the patient is already on maximally tolerated doses. Addition of nitrate in this patient may worsen orthostatic hypotension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise echocardiography</span></strong><span style=\"font-size:12.0pt\">: May provide prognostic information but doesn&#39;t identify lesions for revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the setting of persistent symptoms despite maximally tolerated medical therapy, invasive imaging for revascularization assessment is appropriate to improve symptom status and quality of life.</span></span></span></p>",
      "correct_choice_id": 26995,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19783,
      "choices": [
        {
          "id": 79093,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abdominal aortography</span></span></span></p>"
        },
        {
          "id": 79094,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACE inhibitor therapy </span></span></span></p>"
        },
        {
          "id": 79095,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
        },
        {
          "id": 79096,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Open abdominal aortic aneurysm repair</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with a 6.1 cm abdominal aortic aneurysm (AAA) detected on routine USG screening. What is the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q2672989",
      "question_audio": null,
      "question_video": null,
      "map_id": 30646,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CT angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography is the preferred imaging modality for accurately assessing the size, location, and morphology of the AAA, which is crucial for planning repair.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Abdominal aortography</span></strong><span style=\"font-size:12.0pt\">: Invasive and less commonly used for AAA evaluation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ACE inhibitor therapy</span></strong><span style=\"font-size:12.0pt\">: Doesn&#39;t address the need for repair of a large AAA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Open AAA repair</span></strong><span style=\"font-size:12.0pt\">: Premature before confirming the location and suitability for repair with CTA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The U.S. Preventive Services Task Force recommends one-time screening with duplex ultrasonography in all men aged 65 to 75 years who have smoked at least 100 cigarettes in their lifetime and selective screening in men in this age group who have never smoked.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography or magnetic resonance angiography is the imaging procedure of choice to identify the exact location of an abdominal aneurysm and plan operative repair.</span></span></span></p>",
      "correct_choice_id": 79095,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19784,
      "choices": [
        {
          "id": 79097,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 79098,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest compressions </span></span></span></p>"
        },
        {
          "id": 79099,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous atropine </span></span></span></p>"
        },
        {
          "id": 79100,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Isoproterenol</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with Alzheimer&#39;s disease, on donepezil, presents with somnolence, hypotension (70/40 mmHg), and sinus bradycardia (30/min). What is the next treatment?</span></span></p>",
      "unique_key": "Q1533560",
      "question_audio": null,
      "question_video": null,
      "map_id": 30647,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Intravenous atropine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with symptomatic bradycardia (altered mental status, hypotension), intravenous atropine is the first-line treatment to increase heart rate and improve perfusion. Donepezil, a cholinesterase inhibitor used in Alzheimer&#39;s, is a common cause of drug-induced bradycardia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug, not indicated for bradycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chest compressions</span></strong><span style=\"font-size:12.0pt\">: Not indicated if the patient has a pulse. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Isoproterenol</span></strong><span style=\"font-size:12.0pt\">: Second-line chronotropic agent, considered if atropine is ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The treatment of hemodynamically unstable bradycardia with a pulse is intravenous atropine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common extrinsic cause of sinus bradycardia is medication use (&beta;-blockers, donepezil, neostigmine, pyridostigmine).</span></span></span></p>",
      "correct_choice_id": 79099,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19785,
      "choices": [
        {
          "id": 79101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiography </span></span></span></p>"
        },
        {
          "id": 79102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apixaban </span></span></span></p>"
        },
        {
          "id": 79103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Unfractionated heparin </span></span></span></p>"
        },
        {
          "id": 79104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old man with a history of atrial fibrillation, diabetes, and peripheral artery disease presents with acute left leg pain, absent pulses, and cold, mottled skin. What is the most appropriate next step?</span></span></p>",
      "unique_key": "Q4623786",
      "question_audio": null,
      "question_video": null,
      "map_id": 30648,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Unfractionated heparin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with acute limb ischemia (ALI). Immediate anticoagulation with unfractionated heparin is crucial to prevent further thrombus propagation while awaiting definitive intervention (angiography).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Angiography</span></strong><span style=\"font-size:12.0pt\">: Essential for diagnosis and planning revascularization, but anticoagulation should be started first. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Apixaban</span></strong><span style=\"font-size:12.0pt\">: Oral anticoagulant, not appropriate in the acute setting of ALI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Not indicated for ALI, which is an arterial problem.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treat acute limb ischemia with anticoagulation.</span></span></span></p>",
      "correct_choice_id": 79103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19786,
      "choices": [
        {
          "id": 79105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 79106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
        },
        {
          "id": 79107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propranolol </span></span></span></p>"
        },
        {
          "id": 79108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reassurance</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with no medical history presents with frequent, bothersome palpitations that subside with exercise and in the nights. ECG is shown. Echo and baseline lab tests including CBC and TFT are normal. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-172502.png\" style=\"height:138px; width:300px\" /></span></span></p>",
      "unique_key": "Q2886254",
      "question_audio": null,
      "question_video": null,
      "map_id": 30650,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Propranolol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has symptomatic premature ventricular contractions (PVCs) that are bothersome. Beta-blockers are the first-line treatment for symptomatic PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential toxicity, not first-line for simple PVCs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: Not helpful for diagnosing PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reassurance</span></strong><span style=\"font-size:12.0pt\">: Not sufficient for bothersome symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers are the first-line treatment for symptomatic PVCs in patients without structural heart disease.</span></span></span></p>",
      "correct_choice_id": 79107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54145,
      "choices": [
        {
          "id": 216049,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography </span></span></span></p>"
        },
        {
          "id": 216050,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eplerenone </span></span></span></p>"
        },
        {
          "id": 216051,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen per nasal cannula </span></span></span></p>"
        },
        {
          "id": 216052,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent coronary angiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man presents with recurrent chest pain and elevated troponin. ECG is shown. remains in pain despite aspirin, clopidogrel, heparin, and nitroglycerin. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-173300.png\" style=\"height:256px; width:300px\" /></span></span></p>",
      "unique_key": "Q9684555",
      "question_audio": null,
      "question_video": null,
      "map_id": 30629,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Urgent coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has NSTE-ACS with refractory angina despite medical therapy. Urgent coronary angiography is indicated to identify the culprit lesion and potentially perform revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Echocardiography</span></strong><span style=\"font-size:12.0pt\">: May be helpful, but not the immediate priority. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eplerenone</span></strong><span style=\"font-size:12.0pt\">: Indicated in certain post-MI patients, but not the immediate priority for refractory angina. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oxygen per nasal cannula</span></strong><span style=\"font-size:12.0pt\">: Indicated only if the patient is hypoxic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urgent or immediate diagnostic angiography with intent to perform revascularization is indicated in patients with NSTE-ACS who have refractory angina or hemodynamic or electrical instability.</span></span></span></p>",
      "correct_choice_id": 216052,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54147,
      "choices": [
        {
          "id": 216057,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
        },
        {
          "id": 216058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
        },
        {
          "id": 216059,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin </span></span></span></p>"
        },
        {
          "id": 216060,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pramlintide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with type 2 diabetes, hypertension, hyperlipidemia, and aortofemoral bypass surgery 2 years ago has an HbA1c of 7.1%. His current medications are metformin, atenolol, ramipril, amlodipine, aspirin, rivaroxaban, and atorvastatin. Which medication is most appropriate to add for cardiovascular risk reduction?</span></span></p>",
      "unique_key": "Q8365159",
      "question_audio": null,
      "question_video": null,
      "map_id": 30631,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Liraglutide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP-1 receptor agonists like liraglutide have been shown to reduce cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), which this patient has due to his history of bypass surgery. Liraglutide also promotes weight loss, which can be beneficial for this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Patient is already on rivaroxaban and aspirin. Addition of clopidogrel would not provide any additional benefit and only increase the bleeding risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: No longer recommended for routine use due to lack of benefit and side effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pramlintide</span></strong><span style=\"font-size:12.0pt\">: Amylin analog used for glycemic control, no proven cardiovascular benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are associated with reduced rates of adverse cardiovascular events, including stroke, myocardial infarction, and cardiovascular death, compared with placebo.</span></span></span></p>",
      "correct_choice_id": 216058,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54149,
      "choices": [
        {
          "id": 216065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin</span></span></span></p>"
        },
        {
          "id": 216066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ezetimibe </span></span></span></p>"
        },
        {
          "id": 216067,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin</span></span></span></p>"
        },
        {
          "id": 216068,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No changes in management</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 59-year-old man with type 2 diabetes and a history of stroke is on aspirin, metformin, olmesartan, and rosuvastatin. His LDL-C is 66 mg/dL, HDL-C is 28 mg/dL and HbA1c is 6.8%. What additional medication should be considered for CV risk reduction?</span></span></p>",
      "unique_key": "Q1218758",
      "question_audio": null,
      "question_video": null,
      "map_id": 30633,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Empagliflozin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors like empagliflozin have been shown to reduce cardiovascular events in patients with type 2 diabetes and established ASCVD. They are recommended as part of a comprehensive cardiovascular risk reduction strategy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ezetimibe</span></strong><span style=\"font-size:12.0pt\">: Not indicated as LDL cholesterol is already well-controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: Can increase HDL but no longer recommended for routine use due to lack of benefit and side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No changes in management</span></strong><span style=\"font-size:12.0pt\">: Inadequate as SGLT2 inhibitors provide additional CV benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider adding SGLT2 inhibitors to the treatment regimen for patients with type 2 diabetes and established ASCVD to reduce CV risk.</span></span></span></p>",
      "correct_choice_id": 216065,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54151,
      "choices": [
        {
          "id": 216073,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add amlodipine </span></span></span></p>"
        },
        {
          "id": 216074,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decrease lisinopril dosage </span></span></span></p>"
        },
        {
          "id": 216075,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduce isosorbide mononitrate&nbsp;dosage&nbsp;to once daily </span></span></span></p>"
        },
        {
          "id": 216076,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat coronary angiography</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with CAD and diabetes mellitus experiences worsening angina. He is currently on ramipril, diltiazem, metformin, atorvastatin and isosorbide mononitrate twice daily. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q4464879",
      "question_audio": null,
      "question_video": null,
      "map_id": 30634,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Reduce isosorbide mononitrate dosage to once daily</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is likely experiencing nitrate tolerance, a common side effect of long-acting nitrates like isosorbide mononitrate. Reducing the frequency to once daily with a nitrate-free interval helps restore nitrate efficacy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adding amlodipine</span></strong><span style=\"font-size:12.0pt\">: Not the first-line option when nitrate tolerance is suspected. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreasing lisinopril</span></strong><span style=\"font-size:12.0pt\">: Not indicated as blood pressure is controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Repeat coronary angiography</span></strong><span style=\"font-size:12.0pt\">: Not necessary unless there is a suspicion of new coronary lesions or progression of existing ones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Long-acting nitrates provide a constant level of vasodilation and symptom relief throughout the day, but a nitrate-free interval is required to avoid tolerance.</span></span></span></p>",
      "correct_choice_id": 216075,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54152,
      "choices": [
        {
          "id": 216077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
        },
        {
          "id": 216078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperbaric oxygen treatment </span></span></span></p>"
        },
        {
          "id": 216079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive angiography </span></span></span></p>"
        },
        {
          "id": 216080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary below-the-knee amputation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 80-year-old man with diabetes, hypertension, and hyperlipidemia presents with a 6-week history of resting foot pain and a non-healing ulcer. His ankle-brachial index (ABI) is 0.44 on the right and 0.62 on the left. What is the most appropriate next step?</span></span></p>",
      "unique_key": "Q5414900",
      "question_audio": null,
      "question_video": null,
      "map_id": 30635,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Invasive angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has chronic limb-threatening ischemia (CLTI) based on his rest pain and non-healing ulcer. Invasive angiography is the most appropriate next step to assess the arterial anatomy and determine the best revascularization strategy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CT angiography</span></strong><span style=\"font-size:12.0pt\">: Can be helpful but is not the first step for patients with CLTI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hyperbaric oxygen treatment</span></strong><span style=\"font-size:12.0pt\">: Not a primary treatment for CLTI, but may be adjunctive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Primary amputation</span></strong><span style=\"font-size:12.0pt\">: Not the initial approach in patients with potentially salvageable limbs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chronic limb-threatening ischemia (CLTI) is characterized by more than 2 weeks of ischemic rest pain, nonhealing wound/ulcers, or gangrene in one or both legs that is attributable to objectively proven peripheral artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with CLTI, immediate invasive angiography with endovascular revascularization is often the most effective strategy to preserve tissue viability.</span></span></span></p>",
      "correct_choice_id": 216079,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54153,
      "choices": [
        {
          "id": 216081,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery calcium scoring </span></span></span></p>"
        },
        {
          "id": 216082,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CT angiography </span></span></span></p>"
        },
        {
          "id": 216083,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive coronary angiography </span></span></span></p>"
        },
        {
          "id": 216084,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old woman with chest pain over 24 hours and it is worsening despite multiple doses of NTG. She is known case of hypertension and dyslipidaemia and on enalapril and rosuvastatin. Her ECG 3 months ago was normal and her current ECG in the ER is shown. Her initial troponin is normal. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-174508.png\" style=\"height:219px; width:400px\" /></span></span></p>",
      "unique_key": "Q1938886",
      "question_audio": null,
      "question_video": null,
      "map_id": 30636,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Invasive coronary angiography</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Coronary angiography should also be considered for patients with ischemic symptoms that are refractory to medication, such as this patient with unstable angina refractory to medical therapy. If culprit lesions amenable to intervention are identified during diagnostic coronary angiography, percutaneous revascularization can be performed</span><span style=\"font-size:12.0pt\">.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coronary artery calcium scoring</span></strong><span style=\"font-size:12.0pt\">: No use in patients who are already receiving statins and not helpful in the acute setting.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coronary CT angiography</span></strong><span style=\"font-size:12.0pt\">: May be considered, but invasive angiography is preferred for immediate diagnosis and potential intervention. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: C/I in the context of acute/ongoing ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive coronary angiography is the preferred diagnostic test in patients with refractory angina to assess coronary anatomy and guide potential revascularization. </span></span></span></p>",
      "correct_choice_id": 216083,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54154,
      "choices": [
        {
          "id": 216085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ambulatory ECG monitoring </span></span></span></p>"
        },
        {
          "id": 216086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Discontinue flecainide </span></span></span></p>"
        },
        {
          "id": 216087,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Discontinue metoprolol </span></span></span></p>"
        },
        {
          "id": 216088,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise stress testing</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents with inferior STEMI and he is successfully treated with PCI. He has a history of paroxysmal AF and was taking flecainide. He was also started on rivaroxaban, metoprolol, and ramipril post PCI. He is currently asymptomatic and now planned for discharge from the hospital. What is the most appropriate management?</span></span></span></p>",
      "unique_key": "Q8773956",
      "question_audio": null,
      "question_video": null,
      "map_id": 30638,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Discontinue flecainide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This patient has ischemic heart disease and previously diagnosed paroxysmal atrial fibrillation (AF). Amiodarone, dofetilide, flecainide, propafenone, sotalol, and dronedarone may be used to maintain sinus rhythm in patients with AF. Antiarrhythmic drug selection is guided by the patient&#39;s comorbid conditions and safety considerations. Flecainide is a class IC antiarrhythmic agent and, along with propafenone, is absolutely contraindicated in patients with ischemic heart disease, given the increased risk for ventricular arrhythmias in this population. This patient also has evidence of left ventricular (LV) dysfunction on a post&ndash;myocardial infarction echocardiogram, which may be due to infarcted myocardium and may lead to increased long-term risk for ventricular arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ambulatory ECG monitoring</span></strong><span style=\"font-size:12.0pt\">: Helpful for assessing AF burden but doesn&#39;t address the contraindication of flecainide. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Discontinue metoprolol</span></strong><span style=\"font-size:12.0pt\">: Not ideal as it&#39;s essential for managing ischemic heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise stress testing</span></strong><span style=\"font-size:12.0pt\">: Not recommended immediately post-MI, especially with existing conduction abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IC antiarrhythmics like flecainide are C/I in patients with ischemic heart disease due to an increased risk of ventricular arrhythmias and death. </span></span></span></p>",
      "correct_choice_id": 216086,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54155,
      "choices": [
        {
          "id": 216089,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinuation of cardioprotective medications </span></span></span></p>"
        },
        {
          "id": 216090,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Improvement in symptoms </span></span></span></p>"
        },
        {
          "id": 216091,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased survival </span></span></span></p>"
        },
        {
          "id": 216092,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced risk for myocardial infarction</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 58-year-old man with stable angina has persistent symptoms despite maximally tolerated medical therapy. Coronary Angiogram shows 70% proximal RCA stenosis and 80% obtuse marginal artery stenosis. What benefit can the patient expect from CABG?</span></span></span></p>",
      "unique_key": "Q3206084",
      "question_audio": null,
      "question_video": null,
      "map_id": 30639,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Improvement in symptoms</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The primary goal of revascularization in patients with stable angina is symptom relief and improved quality of life. While CABG may also offer a survival benefit in patients with multivessel disease or left main stenosis and/or LV dysfunction, this patient&#39;s anatomy does not meet those criteria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinuation of medications</span></strong><span style=\"font-size:12.0pt\">: Not recommended after CABG. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased survival</span></strong><span style=\"font-size:12.0pt\">: Less likely in this patient without multivessel or left main disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduced risk of MI</span></strong><span style=\"font-size:12.0pt\">: Possible, but not the primary goal in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary goal of revascularization instable angina is symptom relief.</span></span></span></p>",
      "correct_choice_id": 216090,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54157,
      "choices": [
        {
          "id": 216097,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ranolazine </span></span></span></p>"
        },
        {
          "id": 216098,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&beta;-Blockers </span></span></span></p>"
        },
        {
          "id": 216099,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
        },
        {
          "id": 216100,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrates</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old man with a history of hypertension and hypercholesterolemia has chronic stable angina. Which of the following medications have been shown to reduce mortality and risk of myocardial infarction (MI)?</span></span></p>",
      "unique_key": "Q2389135",
      "question_audio": null,
      "question_video": null,
      "map_id": 30640,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Aspirin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with chronic stable angina, aspirin (ASA) has been shown to reduce the risk of myocardial infarction (MI) and mortality. Apart from ASA, statins and ACEi (in selected patients) have shown to reduce mortality as well. Surprisingly, none of the antianginals have shown to improve survival (they provide symptomatic benefit though). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ranolazine:</span></strong><span style=\"font-size:12.0pt\"> Ranolazine is a newer anti-anginal medication that works by reducing myocardial oxygen demand. While it is effective in relieving angina symptoms, it has not been shown to reduce mortality or MI risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. &beta;-Blockers:</span></strong><span style=\"font-size:12.0pt\"> Beta-blockers are first-line therapy for chronic stable angina. They reduce myocardial oxygen demand by decreasing heart rate and contractility. While they are effective in controlling angina symptoms and improving exercise tolerance, their impact on mortality is less clear.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nitrates:</span></strong><span style=\"font-size:12.0pt\"> Nitrates are potent vasodilators that improve myocardial blood flow and reduce angina symptoms. They are primarily used for symptom relief and do not have a significant impact on mortality or MI risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin reduces mortality and MI risk in patients with chronic stable angina.</span></span></span></p>",
      "correct_choice_id": 216099,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54158,
      "choices": [
        {
          "id": 216101,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
        },
        {
          "id": 216102,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac catheterization</span></span></span></p>"
        },
        {
          "id": 216103,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardioversion </span></span></span></p>"
        },
        {
          "id": 216104,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old man with a history of hypertension and CAD presents with recurrent atrial flutter. He is on dabigatran, metoprolol, ramipril, aspirin, and atorvastatin. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q4144421",
      "question_audio": null,
      "question_video": null,
      "map_id": 30641,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Catheter ablation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the definitive treatment for typical atrial flutter, with a high success rate (&gt; 95%) and low complication rate. It&#39;s the most appropriate option for this patient with recurrent symptomatic atrial flutter despite rate control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential for toxicity, not the first-line treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cardiac catheterization</span></strong><span style=\"font-size:12.0pt\">: Not needed for treating atrial flutter at this point. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cardioversion</span></strong><span style=\"font-size:12.0pt\">: May provide temporary relief but is not definitive treatment in this case where the patient is experiencing recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the best treatment for recurrent typical atrial flutter.</span></span></span></p>",
      "correct_choice_id": 216104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54159,
      "choices": [
        {
          "id": 216105,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase carvedilol </span></span></span></p>"
        },
        {
          "id": 216106,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase digoxin </span></span></span></p>"
        },
        {
          "id": 216107,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase lisinopril </span></span></span></p>"
        },
        {
          "id": 216108,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start Noradrenaline</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 75-year-old woman with ischemic cardiomyopathy presents with progressive dyspnea, edema and confusion. Her medications include low-dose aspirin, furosemide, carvedilol, ramipril, digoxin, and spironolactone. Her BP is 84/52 mm Hg, PR is 118/min, RR is 28/min and SpO2 is 95 in room air. Her reports are shown below. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ALT - 172 U/L, AST - 163 U/L, S. Creatinine - 2.9 mg/dL , S. K - 4.7 mEq/L, S. Na - 132 mEq/L &amp; S. Digoxin - 0.3 ng/mL.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the most appropriate initial treatment?</span></span></span></p>",
      "unique_key": "Q5304020",
      "question_audio": null,
      "question_video": null,
      "map_id": 30642,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Start Nonadrenaline</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has cardiogenic shock due to acute decompensated heart failure (ADHF). Noradrenaline (NA), an inotrope, is indicated to improve cardiac output in this scenario. Once NA is added, other inotropes like dobutamine and/or milrinone can be added sequentially to ensure adequate support. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase carvedilol</span></strong><span style=\"font-size:12.0pt\">: Beta-blockers are contraindicated in cardiogenic shock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Increase digoxin</span></strong><span style=\"font-size:12.0pt\">: Not effective in cardiogenic shock and potentially harmful with AKI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase lisinopril</span></strong><span style=\"font-size:12.0pt\">: Afterload reduction may be considered later, but inotropic support is the priority in this patient with cardiogenic shock.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with cardiogenic shock, inotropes such as Noradrenaline, dobutamine or milrinone may be considered to improve cardiac function.</span></span></span></p>",
      "correct_choice_id": 216108,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54160,
      "choices": [
        {
          "id": 216109,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add clopidogrel </span></span></span></p>"
        },
        {
          "id": 216110,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add oral anticoagulation </span></span></span></p>"
        },
        {
          "id": 216111,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue aspirin and begin oral anticoagulation </span></span></span></p>"
        },
        {
          "id": 216112,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No change in therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old asymptomatic woman with CAD, diabetes and hypertension presents with palpitations. ECG shows AF. She is on metoprolol, telmisartan, aspirin, and atorvastatin. What is the most appropriate treatment?</span></span></p>",
      "unique_key": "Q2690057",
      "question_audio": null,
      "question_video": null,
      "map_id": 30643,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Discontinue aspirin and begin oral anticoagulation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has AF and is at high risk for stroke (CHA2DS2-VASc score of 5). Oral anticoagulation is indicated for stroke prevention. Aspirin should be discontinued as it provides no additional benefit and increases bleeding risk when combined with anticoagulants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adding clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Not indicated, as the patient has no recent ACS or stent. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adding oral anticoagulation without discontinuing aspirin</span></strong><span style=\"font-size:12.0pt\">: Increases bleeding risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No change in therapy</span></strong><span style=\"font-size:12.0pt\">: Inadequate as the patient needs anticoagulation for stroke prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For most patients with high-risk atrial fibrillation and stable coronary artery disease, oral anticoagulation therapy without an antiplatelet agent is sufficient for prevention of both acute coronary syndromes and thromboembolism.</span></span></span></p>",
      "correct_choice_id": 216111,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}